These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 16263739)

  • 21. Assessment of phosphorus and calcium metabolism and its clinical management in hemodialysis patients in the community of Valencia.
    Maduell F; Gorriz JL; Pallardo LM; Pons R; Santiago C;
    J Nephrol; 2005; 18(6):739-48. PubMed ID: 16358233
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mineral metabolism and haemoglobin concentration among haemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS).
    Kimata N; Akiba T; Pisoni RL; Albert JM; Satayathum S; Cruz JM; Akizawa T; Andreucci VE; Young EW; Port FK
    Nephrol Dial Transplant; 2005 May; 20(5):927-35. PubMed ID: 15728270
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Application of NKF-K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease: changes of clinical practices and their effects on outcomes and quality standards in three haemodialysis units.
    Arenas MD; Alvarez-Ude F; Gil MT; Soriano A; Egea JJ; Millán I; Amoedo ML; Muray S; Carretón MA
    Nephrol Dial Transplant; 2006 Jun; 21(6):1663-8. PubMed ID: 16464885
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [CA-P control in haemodialysis and K/DOQI guidelines].
    Rivera F; Sánchez de la Nieta MD; Echarri R; Anaya S; Carreño A; Vozmediano MC; Alcaide MP
    Nefrologia; 2006; 26(3):351-7. PubMed ID: 16892824
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of calcium and phosphorus metabolism in hemodialysis patients in Tehran Province, Iran.
    Mahdavi-Mazdeh M; Zamyadi M; Norouzi S; Heidary Rouchi A
    Iran J Kidney Dis; 2007 Jul; 1(1):25-8. PubMed ID: 19357440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence, clinical correlates and therapy cost of mineral abnormalities among haemodialysis patients: a cross-sectional multicentre study.
    Lorenzo V; Martin-Malo A; Perez-Garcia R; Torregrosa JV; Vega N; de Francisco AL; Cases A
    Nephrol Dial Transplant; 2006 Feb; 21(2):459-65. PubMed ID: 16263739
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phosphate binder therapy for attainment of K/DOQI bone metabolism guidelines.
    Nolan CR
    Kidney Int Suppl; 2005 Jul; (96):S7-14. PubMed ID: 15954948
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and clinical consequences of elevated Ca x P product in hemodialysis patients.
    Block GA
    Clin Nephrol; 2000 Oct; 54(4):318-24. PubMed ID: 11076108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mineral metabolism disturbances in patients with chronic kidney disease.
    Kestenbaum B; Belozeroff V
    Eur J Clin Invest; 2007 Aug; 37(8):607-22. PubMed ID: 17635571
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Investigation of phosphorus calcium metabolism after oral phosphorus supplementation].
    Renier JC; Giraud P; Girardeau C; Jallet P; Gillabert P; Audran M
    Rev Rhum Mal Osteoartic; 1992 Oct; 59(9):537-44. PubMed ID: 1494736
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Calcium and phosphorus metabolism in maintenance hemodialysis.
    Ritz E; Mehls O; Krempien B
    Adv Nephrol Necker Hosp; 1980; 9():71-108. PubMed ID: 6773320
    [No Abstract]   [Full Text] [Related]  

  • 33. Bone metabolism and disease--K/DOQI impact on nurses and dietitians.
    Knapp S
    Nephrol Nurs J; 2004; 31(3):333-5. PubMed ID: 15303430
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of hyperphosphatemia in patients with chronic kidney disease on maintenance hemodialysis: results of the CARE study.
    Qunibi WY; Nolan CR
    Kidney Int Suppl; 2004 Sep; (90):S33-8. PubMed ID: 15296505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The effects of calcium and phosphorus in hemodialysis.
    Goldsmith RS
    Annu Rev Med; 1976; 27():181-90. PubMed ID: 180871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calcium and phosphorus metabolism in patients who have chronic kidney disease.
    Goodman WG
    Med Clin North Am; 2005 May; 89(3):631-47. PubMed ID: 15755471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Evidence basis for integrated management of mineral metabolism in patients with end-stage renal disease.
    Scialla JJ
    Curr Opin Nephrol Hypertens; 2018 Jul; 27(4):258-267. PubMed ID: 29677006
    [TBL] [Abstract][Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.